RANDOLPH
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | <u>SIR</u> | | Exp | <u>Obs</u> | SIR | |
|----------------------|--------------------|--------------|------------------|-------------------------|------------------------|------------|-----|--|
| Bladder, Urinary | | | | Melanoma of Skin | | | | |
| Male | 20.27 | 16 | 79 | Male | 12.18 | 11 | 90 | |
| Female | 7.97 | 11 | 138 | Female | 10.00 | 12 | 120 | |
| Total | 28.24 | 27 | 96 | Total | 22.17 | 23 | 104 | |
| Brain and Oth | er Central N | ervous Syste | Multiple Myeloma | | | | | |
| Male | 6.64 | 5 | 75 | Male | 3.78 | 4 | NC* | |
| Female | 5.90 | 4 | NC* | Female | 3.63 | 4 | NC* | |
| Total | 12.54 | 9 | 72 | Total | 7.41 | 8 | 108 | |
| Breast | <u>nst</u> | | | | Non-Hodgkin's Lymphoma | | | |
| Male | 1.31 | 1 | NC* | Male | 16.08 | 17 | 106 | |
| Female | 127.94 | 117 | 91 | Female | 14.57 | 10 | 69 | |
| Total | 129.25 | 118 | 91 | Total | 30.65 | 27 | 88 | |
| Cervix Uteri | | | | Oral Cavity and Pharynx | | | | |
| | | | | Male | 13.28 | 19 | 143 | |
| Female | 8.19 | 8 | 98 | Female | 6.65 | 6 | 90 | |
| | | | | Total | 19.93 | 25 | 125 | |
| Colon / Rectum | | | | <u>Ovary</u> | | | | |
| Male | 51.33 | 51 | 99 | | | | | |
| Female | 51.18 | 63 | 123 | Female | 15.40 | 20 | 130 | |
| Total | 102.51 | 114 | 111 | | | | | |
| Esophagus | | | | Pancreas | | | | |
| Male | 7.35 | 2 | NC* | Male | 7.74 | 8 | 103 | |
| Female | 2.64 | 3 | NC* | Female | 8.45 | 5 | 59 | |
| Total | 9.99 | 5 | 50 | Total | 16.18 | 13 | 80 | |
| Hodgkin's Dis | <u>ease</u> | | Prostate | | | | | |
| Male | 3.22 | 2 | NC* | Male | 124.92 | 144 | 115 | |
| Female | 2.57 | 1 | NC* | | | | | |
| Total | 5.79 | 3 | NC* | | | | | |
| Kidney and R | <u>enal Pelvis</u> | | Stomach | | | | | |
| Male | 11.81 | 13 | 110 | Male | 8.73 | 11 | 126 | |
| Female | 7.32 | 9 | 123 | Female | 5.50 | 5 | 91 | |
| Total | 19.13 | 22 | 115 | Total | 14.22 | 16 | 112 | |
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 7.17 | 5 | 70 | Male | 4.63 | 7 | 151 | |

| Female | 2.08 | 2 | NC* | | | | | |
|--|--------|-----|-----|----------------|--------------------------------------|-----|--------|--|
| Total | 9.25 | 7 | 76 | | | | | |
| Leukemia | | | | Thyroid | | | | |
| Male | 8.69 | 12 | 138 | Male | 2.45 | 4 | NC* | |
| Female | 6.80 | 8 | 118 | Female | 6.56 | 11 | 168 | |
| Total | 15.49 | 20 | 129 | Total | 9.02 | 15 | 166 | |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corp | Uteri, Corpus and Uterus, NOS | | | |
| Male | 4.07 | 6 | 147 | | | | | |
| Female | 1.75 | 3 | NC* | Female | 24.63 | 18 | 73 | |
| Total | 5.82 | 9 | 155 | | | | | |
| Lung and Bronchus | | | | All Sites / T | All Sites / Types | | | |
| Male | 65.66 | 74 | 113 | Male | 409.52 | 444 | 108 | |
| Female | 51.39 | 65 | 126 | Female | 400.38 | 423 | 106 | |
| Total | 117.04 | 139 | 119 | Total | 809.90 | 867 | 107 #+ | |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels